Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 10428119
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
granted -
US 10428313
Chimeric West Nile/Dengue viruses and methods of use
granted -
US 10428133
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
granted -
US 10428025
Antifungal compound process
granted -
US 10426830
Altering the immundominance hierarchy using a DNA vaccine expressing conserved regions
granted -
US 10426797
Compositions and methods for treating cancer with anti-CD33 immunotherapy
granted -
US 10420832
Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
granted -
US 10420834
Recombinant metapneumovirus F proteins and their use
granted -
US 10421952
Mutant organophosphorus acid anhydrolase enzymes having increased catalytic efficiency on V-agents
granted -
US 10421945
Agents and methods to elicit anti-tumor immune response
granted -
US 10420829
Chlamydia vaccine
granted -
US 10421802
Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
granted -
US 10421805
Anti-hepatitis C antibodies and antigen binding fragments thereof
granted -
US 10415044
Adeno-associated virus vectors encoding modified G6PC and uses thereof
granted -
US 10413527
Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV
granted -
US 10413548
Methods and compositions for the inhibition of Pin1
granted -
US 10407392
Antifungal compound process
granted -
US 10406177
Modified cells and methods of therapy
granted -
US 10407485
Murine anti-NY-ESO-1 T cell receptors
granted -
US 10400015
Recombinant HIV-1 envelope proteins and their use
granted -
US 10399943
Antifungal compound process
granted -
US 10398772
Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
granted -
US 10398721
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
granted -
US 10400031
Identification of antibodies specific for lyssaviruses and methods of their use
granted -
US 10399189
Airfoil aerodynamics
granted -
US 10392441
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
granted -
US 10392365
Antifungal compound process
granted -
US 10385319
Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
granted -
US 10383945
Methods for DNA-dependent targeting of a cell permeant antibody
granted -
US 10383960
Small molecule imaging of fungi by positron emission tomography scanning
granted -
US 10377798
Recombinant respiratory syncytial virus G protein fragments
granted -
US 10376558
Method and compositions for synchronizing time of insemination in gilts
granted -
US 10376525
Treprostinil administration by inhalation
granted -
US 10376495
Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
granted -
US 10370348
Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
granted -
US 10369208
Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins
granted -
US 10370439
Prevention of tissue ischemia and related methods
granted -
US 10363301
Stabilized influenza hemagglutinin stem region trimers and uses thereof
granted -
US 10363292
Vaccination with anti-tick antigens to control multiple tick species and disease transmission in white-tailed deer and other host animals
granted -
US 10363286
Peptide inhibition of CCR3-mediated diseases or conditions
granted -
US 10363294
Yeast-brachyury immunotherapeutic compositions
granted -
US 10363289
Mutant OPAA enzyme with increased catalytic efficiency on GP
granted -
US 10363213
Immunogenic composition against Campylobacter jejuni
granted -
US 10358481
Engineered antibody constant domain molecules
granted -
US 10357522
Bacteriophage compositions and methods of selection of components against specific bacteria
granted -
US 10357554
AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
granted -
US 10351587
Method of making and using 7Ξ±, 11Ξ²-dimethyl-17Ξ²-hydroxyestr-4-en-3-one 17-undecanoate
granted -
US 10350273
Treatment of hormonal disorders of growth
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory